425: BioNTech to Acquire CureVac in $1.25 Billion All-Stock Deal, Bolstering mRNA Oncology Pipeline

BioNTech SE announced a definitive agreement to acquire CureVac N.V. in an all-stock transaction valued at approximately $1.25 billion, aiming to significantly strengthen its mRNA-based cancer immunotherapy capabilities.

Summary

• BioNTech SE will acquire all outstanding shares of CureVac N.V. through a public exchange offer.
• Each CureVac share will be exchanged for approximately $5.46 in BioNTech American Depositary Shares (ADSs).
• This consideration represents a 55% premium to CureVac's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025.
• The implied aggregate equity value for CureVac in this transaction is approximately $1.25 billion, subject to a collar mechanism.
• The collar mechanism dictates that if BioNTech's 10-day volume weighted average price (VWAP) exceeds $126.55, the exchange ratio will be 0.04318; if the VWAP is lower than $84.37, the exchange ratio will be 0.06476.
• Upon closing, CureVac shareholders are expected to own between 4% and 6% of BioNTech.
• The acquisition is intended to strengthen BioNTech's research, development, manufacturing, and commercialization efforts for investigational mRNA-based cancer immunotherapy candidates.
• It will complement BioNTech's existing capabilities and proprietary technologies in mRNA design, delivery formulations, and manufacturing.
• The transaction is supported by CureVac's major shareholder, dievini Hopp BioTech holding GmbH & Co. KG, and its affiliates, representing 36.76% of CureVac's shares, along with all members of CureVac's management and supervisory boards.
• The German Federal government, through Kreditanstalt für Wiederaufbau (holding 13.32% of CureVac shares), is also expected to support the transaction, bringing total committed support to 50.08% of CureVac shares.
• The transaction is expected to close in 2025, pending customary closing conditions, including a minimum acceptance threshold of at least 80% of CureVac's shares (reducible to 75% by BioNTech) and required regulatory approvals.
• Following the closing, CureVac's operating subsidiary will become a wholly owned subsidiary of BioNTech, and BioNTech plans to integrate CureVac's research and manufacturing site in Tübingen.

Sentiment

Score: 8

Explanation: The document announces a highly strategic and complementary acquisition that offers a significant premium to the acquired company's shareholders and is strongly supported by key stakeholders. It positions BioNTech for accelerated growth in oncology, leveraging its robust financial position and established mRNA expertise. While standard integration and regulatory risks are present, the overall tone and strategic rationale are overwhelmingly positive.

Positives

• The acquisition will significantly strengthen BioNTech's research, development, manufacturing, and commercialization capabilities for mRNA-based cancer immunotherapy candidates.
• It complements BioNTech's proprietary technologies in mRNA design, delivery formulations, and manufacturing, enhancing its overall mRNA platform.
• The transaction marks a key milestone in the execution of BioNTech's oncology strategy, focusing on pan-tumor programs and specific candidates like BNT327.
• The all-stock acquisition has the potential to create long-term value for shareholders of both companies due to complementary capabilities and a shared vision for mRNA innovation.
• CureVac shareholders will receive a substantial 55% premium over their three-month volume-weighted average price, providing immediate value.
• BioNTech's strong financial position, with €15.9 billion in cash, cash equivalents, and security investments as of March 31, 2025, provides a solid foundation for this strategic investment.
• The integration of CureVac's state-of-the-art research and manufacturing site in Tübingen is expected to enhance BioNTech's operational footprint.
• Significant shareholder support, including 50.08% of CureVac's shares committed to tender, increases the likelihood of successful completion.

Negatives

• Existing BioNTech shareholders may experience dilution, as CureVac shareholders are expected to own between 4% and 6% of BioNTech post-closing.
• The transaction is subject to customary closing conditions, including a minimum acceptance threshold of 80% of CureVac shares and regulatory approvals, which may not be satisfied.
• There is a risk of competing offers or acquisition proposals that could complicate or derail the transaction.
• The integration of CureVac's operations and personnel into BioNTech carries inherent risks and potential for disruption.
• The transaction may be more expensive to complete than anticipated, and litigation in connection with the offer could result in significant costs.
• The acquisition may divert management's attention from ongoing business operations and other strategic opportunities.

Risks

• Uncertainties regarding the timing of the exchange offer and the subsequent corporate reorganization of CureVac.
• Uncertainties as to how many of CureVac's shareholders will tender their shares in the exchange offer.
• The risk that competing offers or acquisition proposals will be made.
• The possibility that various conditions to the consummation of the exchange offer and the transactions contemplated by the Purchase Agreement may not be satisfied or waived.
• The possibility of a termination of the Purchase Agreement.
• The ability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing.
• The effects of disruption from the transactions contemplated by the Purchase Agreement and the impact of the announcement and pendency of the transactions on BioNTech's and/or CureVac's business, including their relationships with employees, business partners or governmental entities.
• The risk that the exchange offer or the other transactions contemplated by the Purchase Agreement may be more expensive to complete than anticipated.
• The risk that litigation in connection with the exchange offer or the other transactions contemplated by the Purchase Agreement may result in significant costs of defense, indemnification and liability.
• A diversion of management's attention from ongoing business operations and opportunities as a result of the exchange offer, the other transactions contemplated by the Purchase Agreement or otherwise.
• General industry conditions and competition.
• General political, economic and business conditions, including interest rate, inflation, tariff and currency exchange rate fluctuations, and ongoing geopolitical conflicts.
• The impact of regulatory developments and changes in the United States, Europe and countries outside of Europe, including with respect to tax matters.
• The impact of pharmaceutical industry regulation and health care legislation in the United States, Europe and elsewhere.
• The particular prescribing preferences of physicians and patients.
• Competition from other products.
• Challenges and uncertainties inherent in new product development.
• Ability to obtain or maintain proprietary intellectual property protection.
• Safety, quality, data integrity or manufacturing issues.
• Potential or actual data security and data privacy breaches.

Future Outlook

BioNTech aims to accelerate and broaden the development of mRNA-based medicines for patients in need, particularly in cancer immunotherapy. The company intends to leverage combined capabilities and technologies to advance innovative and transformative cancer treatments and establish new standards of care in the coming years. The all-stock acquisition is expected to create long-term value for shareholders of both companies.

Management Comments

• Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech: "This transaction is another building block in BioNTechs oncology strategy and an investment in the future of cancer medicine. We intend to bring together complementary capabilities and leverage technologies with the goal of advancing the development of innovative and transformative cancer treatments and establishing new standards of care for various types of cancer in the coming years."
• Dr. Alexander Zehnder, CEO of CureVac: "To me, this transaction is more than a business decision, it represents a shared commitment to leverage the full potential of mRNA as a disruptive technology to develop transformative therapies with greater scale and speed. For more than two decades, both companies have operated with related ambitions, often tackling challenges from different angles. This transaction aims at combining complementary scientific capabilities, proprietary technologies, and manufacturing expertise in the mRNA field under one roof."

Industry Context

This acquisition represents a significant consolidation within the mRNA biotechnology sector, particularly as leading players like BioNTech seek to expand their therapeutic pipelines beyond infectious diseases into high-value areas such as oncology. It underscores the industry's growing confidence in mRNA technology's versatility and potential for diverse medical applications. The move reflects a broader trend of strategic mergers and acquisitions aimed at combining complementary scientific expertise, proprietary technologies, and manufacturing capabilities to accelerate the development and commercialization of novel biopharmaceuticals.

Comparison to Industry Standards

• The 55% premium offered to CureVac shareholders is a substantial incentive, aligning with strategic acquisitions in the biotech sector where the acquirer values specific technological synergies or pipeline assets highly.
• BioNTech's robust cash position of €15.9 billion (as of March 31, 2025) provides a strong financial foundation for such a large-scale strategic acquisition, differentiating it from smaller biotech firms that might require additional capital raises for similar transactions.
• The all-stock nature of the deal is a common practice in biotech mergers, allowing for shared future upside and minimizing immediate cash outflow, which can be beneficial for long-term value creation and shareholder alignment.
• The strategic focus on mRNA-based cancer immunotherapy aligns with a major trend in the pharmaceutical industry, where companies are increasingly investing in novel modalities and platforms to address unmet needs in oncology, following the success of mRNA in vaccine development.

Corporate Governance

Legal Proceedings

• There is a risk that litigation in connection with the exchange offer or the other transactions contemplated by the Purchase Agreement may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• Certain shareholders of CureVac, representing 36.76% of CureVac's shares, including dievini Hopp BioTech holding GmbH & Co. KG and certain of its affiliates, and all members of CureVac's management and supervisory boards, have entered into tender and support agreements to tender their shares.
• The German Federal government, through Kreditanstalt für Wiederaufbau (holding 13.32% of CureVac shares), has confirmed a generally positive view of the transaction and is expected to support it by tendering its shares.

Stakeholder Impact

• **Shareholders (CureVac)**: Will receive a significant 55% premium for their shares and will become shareholders in BioNTech, participating in the future growth of a leading mRNA company.
• **Shareholders (BioNTech)**: Expected to benefit from long-term value creation through an expanded and strengthened oncology pipeline and enhanced technological capabilities, though with minor dilution (4-6% ownership by new shareholders).
• **Employees (CureVac)**: CureVac's operating subsidiary will become wholly owned by BioNTech, and its Tübingen site will be integrated, potentially leading to changes in organizational structure and career opportunities within the larger BioNTech entity.
• **Patients/Customers**: The acquisition aims to accelerate the development of innovative mRNA-based cancer treatments, potentially leading to new therapeutic options for patients in need.
• **Business Partners**: Existing relationships with business partners of both companies may be subject to review or change as a result of the integration.

Next Steps

• BioNTech will begin preparing an integration plan for CureVac's operations and site in Tübingen.
• BioNTech intends to file a Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission (SEC) to register the issuance of BioNTech ADSs.
• BioNTech intends to file a Tender Offer Statement on Schedule TO with the SEC, including the offer to exchange/prospectus.
• CureVac intends to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• An extraordinary general meeting of CureVac's shareholders will be convened to adopt resolutions related to the transaction.
• The transaction is expected to close in 2025, subject to satisfaction of customary closing conditions and regulatory approvals.
• Following the closing of the exchange offer, BioNTech and CureVac will effectuate a corporate reorganization of CureVac and its subsidiaries.

Key Dates

Recommendation

Keywords

BioNTech, CureVac, acquisition, mRNA, oncology, cancer immunotherapy, biotechnology, pharmaceutical, exchange offer, strategic transaction, drug development, clinical-stage, BNTX, CVAC